JP2019521105A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521105A5
JP2019521105A5 JP2018563888A JP2018563888A JP2019521105A5 JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5 JP 2018563888 A JP2018563888 A JP 2018563888A JP 2018563888 A JP2018563888 A JP 2018563888A JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
antibody
polymorphism
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521105A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/053245 external-priority patent/WO2017212375A1/en
Publication of JP2019521105A publication Critical patent/JP2019521105A/ja
Publication of JP2019521105A5 publication Critical patent/JP2019521105A5/ja
Pending legal-status Critical Current

Links

JP2018563888A 2016-06-07 2017-06-01 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 Pending JP2019521105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346683P 2016-06-07 2016-06-07
US62/346,683 2016-06-07
PCT/IB2017/053245 WO2017212375A1 (en) 2016-06-07 2017-06-01 Anti-c5 antibody for treating patients with complement c5 polymorphism

Publications (2)

Publication Number Publication Date
JP2019521105A JP2019521105A (ja) 2019-07-25
JP2019521105A5 true JP2019521105A5 (https=) 2020-07-09

Family

ID=59078125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563888A Pending JP2019521105A (ja) 2016-06-07 2017-06-01 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体

Country Status (5)

Country Link
US (1) US20190225678A1 (https=)
EP (1) EP3464351A1 (https=)
JP (1) JP2019521105A (https=)
CN (1) CN109328197A (https=)
WO (1) WO2017212375A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
WO2021034639A1 (en) 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations
CA3153195A1 (en) * 2019-10-25 2021-04-29 John Davis Dosing regimens for treating or preventing c5-associated diseases
US20240415980A1 (en) 2021-10-28 2024-12-19 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CN119409815B (zh) * 2025-01-07 2025-04-08 天辰生物医药(苏州)有限公司 抗人补体c5 vhh抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU2008228247A1 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
MX340696B (es) * 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
WO2014119969A1 (ko) * 2013-01-31 2014-08-07 서울대학교 산학협력단 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CN113956354A (zh) * 2015-01-22 2022-01-21 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法

Similar Documents

Publication Publication Date Title
JP2019521105A5 (https=)
Carroll et al. Weight and metabolic outcomes 12 years after gastric bypass
Dimachkie et al. Chronic inflammatory demyelinating polyneuropathy
Wieszczycka et al. Lanthanides and tissue engineering strategies for bone regeneration
Leyhe et al. Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study
JP2019511222A5 (https=)
Laske Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease
KR102942744B1 (ko) 항-N3pGlu 아밀로이드 베타 항체 및 그의 용도
JP2017518316A5 (https=)
Battaglia et al. Guillain-Barré syndrome following severe head trauma and spine surgery
Fatima et al. Amyloid-β clearance with monoclonal antibodies: transforming Alzheimer’s treatment
HK1248534A1 (zh) 周围神经的igg刺激髓鞘再生
Du et al. The ageing immune system as a potential target of senolytics
Ong et al. Thrombotic paradox: ischaemic stroke in immune thrombocytopaenia. A case report and review
EP3632447A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
JP2015522601A5 (https=)
KR20230145401A (ko) 항-N3pGlu 아밀로이드 베타 항체 및 그의 용도
Stevelink et al. Epilepsy surgery in patients with genetic refractory epilepsy: A systematic review
Nobile-Orazio et al. Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders
Natalia et al. COSTS FOR REVERSE HEMOSTATIC THERAPY OF INTERNAL CEREBRAL BLEEDING WITH THE USE OF PROTHROMBIN COMPLEX CONCENTRATE
Olupot-Olupot et al. Effects of hydroxyurea treatment on malaria infections in Sub-Saharan Africa
Monje et al. DI-022 Real life effectiveness and safety of lenalidomide in the treatment of multiple myeloma
Prins Immunotherapy against amyloid-β in Alzheimer’s disease: an overview
WO2017034906A8 (en) Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
BEZDITKO PHARMACOECONOMIC ANALYSIS OF PROTROMBIN COMPLEX CONCENTRATE (OCTAPLEX PREPARATION) USE IN INTRACEREBRAL HEMORRHAGE